•
Jun 30, 2023

Inhibrx Biosciences Inc Q2 2023 Earnings Report

Total Revenue
$30K
Previous year: $711K
-95.8%
EPS
-$1.08
Previous year: -$0.97
+11.3%
R&D Expense
$34.1M
G&A Expense
$7.26M
Gross Profit
-$701K
Cash and Equivalents
$192M
Free Cash Flow
-$82.6M

Inhibrx Biosciences Inc

Inhibrx Biosciences Inc